All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous systemic treatment (%) previous systemic treatment NO (%) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results A3671009, 2013 0.88 [0.75; 1.04]
Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
CA184-024, 2011 0.72 [0.59; 0.87]
CheckMate 066, 2015 0.42 [0.25; 0.72]
CheckMate 066 DUPLICATE, 2015 0.36 [0.24; 0.55]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs I ; all population), 2015 0.55 [0.42; 0.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.65 [0.53; 0.80]
CheckMate 069 (all population), 2015 0.74 [0.43; 1.27]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49]
CheckMate 238, 2017 0.87 [0.66; 1.14]
EORTC 18071, 2015 0.72 [0.58; 0.89]
IMspire-150 (BRAF mutant), 2020 0.85 [0.65; 1.12]
IMspire-170, 2020 1.06 [0.69; 1.62]
KEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96]
KEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
KEYNOTE-022, 2019 0.76 [0.41; 1.40]
MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.04 [0.83; 1.30]
MDX010 Ipi vs gp100, 2010 0.66 [0.51; 0.86]
0.73 [0.67 ; 0.80 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 22 57% 10,905 low low deaths (OS) (extension)detailed results CA184-024, 2011 0.69 [0.57; 0.84]
CheckMate 066, 2015 0.46 [0.36; 0.59]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.52 [0.42; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.83 [0.67; 1.03]
EORTC 18071, 2015 0.73 [0.64; 0.83]
KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.65 [0.57 ; 0.73 ] CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 66% 4,371 low not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
EORTC 18071, 2015 0.76 [0.63; 0.91]
KEYNOTE 054 (all population), 2018 0.53 [0.37; 0.76]
0.70 [0.58 ; 0.84 ] CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE 054 (all population), 2018 3 36% 2,705 low not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable PFS (extension)detailed results CheckMate 066, 2015 0.42 [0.33; 0.53]
CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.35; 0.51]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.79 [0.65; 0.97]
CheckMate 069 (all population), 2015 0.36 [0.23; 0.57]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27]
KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.53 [0.44 ; 0.64 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 77% 3,595 low not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
CA184-024, 2011 0.76 [0.63; 0.92]
CheckMate 066, 2015 0.43 [0.34; 0.55]
CheckMate 066 DUPLICATE, 2015 0.43 [0.34; 0.55]
CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.31; 0.57]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.74 [0.60; 0.92]
CheckMate 069 (all population), 2015 0.38 [0.23; 0.63]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98]
CheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69]
IMspire-150 (BRAF mutant), 2020 0.78 [0.63; 0.97]
IMspire-170, 2020 1.15 [0.88; 1.50]
KEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64]
KEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
KEYNOTE-022, 2019 0.66 [0.40; 1.08]
0.59 [0.51 ; 0.68 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 17 78% 7,150 low low RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
EORTC 18071, 2015 0.75 [0.63; 0.89]
KEYNOTE 054 (all population), 2018 0.56 [0.47; 0.67]
KEYNOTE 054 (PDL1>1%), 2018 0.57 [0.43; 0.75]
0.65 [0.56 ; 0.76 ] CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 4 57% 3,729 low not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
EORTC 18071, 2015 0.75 [0.63; 0.89]
IMMUNED (N vs P ; all population), 2020 0.56 [0.33; 0.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.40 [0.20; 0.79]
IMMUNED (NI vs P ; all population), 2020 0.23 [0.12; 0.45]
KEYNOTE 054 (all population), 2018 0.57 [0.43; 0.75]
KEYNOTE 054 (PDL1>1%), 2018 0.54 [0.42; 0.69]
0.56 [0.46 ; 0.69 ] CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 7 64% 4,063 low serious DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
CA184-024, 2011 1.15 [0.79; 1.68]
IMspire-170, 2020 0.91 [0.63; 1.32]
1.09 [0.89 ; 1.33 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, IMspire-170, 2020 3 0% 1,675 low not evaluable DMFSdetailed results KEYNOTE 054 (all population), 2018 0.60 [0.49; 0.73]
KEYNOTE 054 (PDL1>1%), 2018 0.60 [0.49; 0.73]
0.60 [0.52 ; 0.69 ] KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 2 0% 1,872 low not evaluable DORdetailed results KEYNOTE-022, 2019 0.41 [0.20; 0.83]
MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
0.59 [0.38 ; 0.92 ] KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010 2 45% 106 low not evaluable DOR (extension)detailed results CheckMate 066, 2015 3.45 [1.46; 8.18]
3.45 [1.46 ; 8.18 ] CheckMate 066, 2015 1 0% 120 NA not evaluable objective responses (ORR)detailed results A3671009, 2013 1.14 [0.69; 1.88]
Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
CA184-024, 2011 1.56 [0.91; 2.65]
CheckMate 066, 2015 4.06 [2.52; 6.54]
CheckMate 066 DUPLICATE, 2015 4.06 [2.52; 6.54]
CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs I ; all population), 2015 6.11 [3.59; 10.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.76 [1.28; 2.41]
CheckMate 069 (all population), 2015 15.08 [8.07; 28.17]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91]
CheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38]
IMspire-150 (BRAF mutant), 2020 1.19 [0.83; 1.71]
IMspire-170, 2020 0.77 [0.50; 1.17]
KEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80]
KEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
KEYNOTE-022, 2019 0.68 [0.32; 1.47]
MDX010 Ipi plus gp100 vs gp100, 2010 4.06 [0.94; 17.43]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.49 [0.25; 0.97]
MDX010 Ipi vs gp100, 2010 8.24 [1.85; 36.76]
2.76 [1.90 ; 4.02 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 21 89% 9,157 low low objective responses (ORR) (extension)detailed results CheckMate 066, 2015 4.50 [2.79; 7.25]
CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs I ; all population), 2015 6.35 [4.38; 9.21]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.96 [4.16; 8.54]
CheckMate 069 (all population), 2015 12.20 [4.41; 33.76]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42]
CheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60]
5.54 [4.14 ; 7.40 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 7 45% 2,592 low not evaluable AE (any grade)detailed results A3671009, 2013 2.22 [1.12; 4.38]
CA184-024, 2011 5.17 [1.48; 18.09]
CheckMate 066, 2015 0.78 [0.34; 1.76]
CheckMate 238, 2017 0.49 [0.20; 1.23]
EORTC 18071, 2015 7.53 [3.17; 17.90]
IMspire-170, 2020 14.27 [3.34; 61.03]
KEYNOTE 054 (all population), 2018 1.51 [0.96; 2.38]
KEYNOTE-022, 2019 2.03 [0.18; 23.06]
MDX010 Ipi plus gp100 vs gp100, 2010 1.95 [0.54; 7.01]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.96 [0.55; 7.07]
MDX010 Ipi vs gp100, 2010 0.99 [0.24; 4.05]
2.07 [1.19 ; 3.60 ] A3671009, 2013, CA184-024, 2011, CheckMate 066, 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMspire-170, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 71% 6,256 low low AE (grade 3-4)detailed results A3671009, 2013 1.84 [1.35; 2.52]
CA184-024, 2011 3.39 [2.34; 4.94]
CheckMate 066, 2015 0.84 [0.56; 1.25]
CheckMate 238, 2017 0.28 [0.21; 0.37]
EORTC 18071, 2015 0.11 [0.08; 0.17]
IMspire-170, 2020 4.03 [2.70; 6.00]
KEYNOTE 054 (all population), 2018 2.03 [1.52; 2.73]
KEYNOTE-022, 2019 2.44 [1.17; 5.12]
MDX010 Ipi plus gp100 vs gp100, 2010 0.94 [0.63; 1.40]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.99 [0.66; 1.47]
MDX010 Ipi vs gp100, 2010 0.95 [0.59; 1.55]
1.10 [0.56 ; 2.13 ] A3671009, 2013, CA184-024, 2011, CheckMate 066, 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMspire-170, 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 97% 6,256 low low AE leading to death (grade 5)detailed results A3671009, 2013 1.71 [0.85; 3.45]
CA184-024, 2011 1.02 [0.02; 51.42]
CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 1.23 [0.42; 3.56]
IMspire-170, 2020 1.39 [0.43; 4.44]
KEYNOTE-022, 2019 4.10 [0.18; 92.93]
1.50 [0.91 ; 2.46 ] A3671009, 2013, CA184-024, 2011, CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020, KEYNOTE-022, 2019 9 0% 2,943 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results A3671009, 2013 97.13 [5.95; 1585.40]
CheckMate 066, 2015 0.55 [0.28; 1.10]
CheckMate 238, 2017 0.15 [0.10; 0.21]
IMMUNED (N vs P ; all population), 2020 3.57 [0.71; 18.07]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.33 [4.34; 29.62]
IMMUNED (NI vs P ; all population), 2020 39.67 [8.72; 180.45]
IMspire-150 (BRAF mutant), 2020 0.78 [0.47; 1.29]
KEYNOTE-022, 2019 2.58 [1.16; 5.75]
2.81 [0.77 ; 10.28 ] A3671009, 2013, CheckMate 066, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-022, 2019 8 95% 2,914 low serious AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 066, 2015 0.61 [0.29; 1.28]
CheckMate 238, 2017 0.11 [0.07; 0.18]
IMMUNED (N vs P ; all population), 2020 4.90 [0.55; 43.46]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.38 [3.94; 32.84]
IMMUNED (NI vs P ; all population), 2020 55.77 [7.19; 432.80]
2.55 [0.30 ; 21.54 ] CheckMate 066, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 5 96% 1,640 low serious SAE (any grade)detailed results A3671009, 2013 3.19 [2.19; 4.65]
CheckMate 066, 2015 0.73 [0.49; 1.10]
IMMUNED (N vs P ; all population), 2020 1.27 [0.56; 2.87]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.69 [1.68; 8.08]
IMMUNED (NI vs P ; all population), 2020 4.55 [2.00; 10.32]
2.14 [0.98 ; 4.66 ] A3671009, 2013, CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 5 89% 1,378 low not evaluable SAE (grade 3-4)detailed results CheckMate 066, 2015 0.74 [0.47; 1.17]
IMMUNED (N vs P ; all population), 2020 2.51 [0.94; 6.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.48 [1.58; 7.66]
IMMUNED (NI vs P ; all population), 2020 8.75 [3.35; 22.86]
2.63 [0.83 ; 8.34 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 4 89% 735 low not evaluable STRAE (any grade)detailed results CheckMate 066, 2015 1.06 [0.54; 2.07]
IMMUNED (N vs P ; all population), 2020 6.13 [1.29; 29.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.69 [2.43; 13.31]
IMMUNED (NI vs P ; all population), 2020 34.09 [7.51; 154.62]
IMspire-150 (BRAF mutant), 2020 1.24 [0.85; 1.81]
KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
1.97 [0.97 ; 3.98 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 88% 2,312 low serious STRAE (grade 3-4)detailed results CheckMate 066, 2015 0.99 [0.44; 2.27]
IMMUNED (N vs P ; all population), 2020 19.34 [1.09; 342.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.68 [1.93; 11.38]
IMMUNED (NI vs P ; all population), 2020 90.55 [5.31; 1542.75]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
4.03 [1.07 ; 15.21 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 67% 1,802 low not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
CA184-024, 2011 5.64 [3.80; 8.35]
CheckMate 066, 2015 0.93 [0.60; 1.46]
CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs I ; all population), 2015 3.70 [1.95; 7.04]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.58 [1.88; 6.81]
CheckMate 069 (all population), 2015 0.75 [0.19; 2.97]
CheckMate 238, 2017 0.25 [0.15; 0.43]
EORTC 18071, 2015 14.40 [10.07; 20.60]
IMMUNED (N vs P ; all population), 2020 4.29 [1.74; 10.57]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.07 [1.04; 24.68]
IMMUNED (NI vs P ; all population), 2020 21.77 [4.78; 99.11]
IMspire-150 (BRAF mutant), 2020 0.82 [0.11; 5.85]
KEYNOTE 054 (all population), 2018 1.79 [1.36; 2.37]
KEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26]
KEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
KEYNOTE-022, 2019 1.36 [0.29; 6.34]
MDX010 Ipi plus gp100 vs gp100, 2010 2.17 [1.28; 3.67]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.99 [1.17; 3.41]
MDX010 Ipi vs gp100, 2010 1.09 [0.60; 1.98]
1.87 [1.22 ; 2.86 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 22 93% 10,517 low low TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
CA184-024, 2011 11.25 [6.30; 20.10]
CheckMate 066, 2015 0.62 [0.35; 1.08]
CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs I ; all population), 2015 3.83 [2.74; 5.36]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.82 [3.41; 6.80]
CheckMate 069 (all population), 2015 3.77 [1.71; 8.31]
CheckMate 238, 2017 0.20 [0.14; 0.27]
EORTC 18071, 2015 25.27 [14.14; 45.18]
IMMUNED (N vs P ; all population), 2020 5.85 [1.58; 21.65]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.66 [2.91; 15.27]
IMMUNED (NI vs P ; all population), 2020 39.00 [10.59; 143.61]
IMspire-150 (BRAF mutant), 2020 1.41 [0.93; 2.12]
KEYNOTE 054 (all population), 2018 4.93 [2.87; 8.48]
KEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91]
KEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
KEYNOTE-022, 2019 3.60 [1.67; 7.74]
MDX010 Ipi plus gp100 vs gp100, 2010 1.64 [0.90; 2.99]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.17 [0.68; 2.01]
MDX010 Ipi vs gp100, 2010 1.41 [0.69; 2.88]
2.19 [1.29 ; 3.72 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 22 96% 10,517 low critical TRAE leading to death (grade 5)detailed results A3671009, 2013 7.00 [0.86; 57.23]
Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
CheckMate 238, 2017 0.25 [0.01; 5.55]
EORTC 18071, 2015 10.16 [0.55; 186.52]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
KEYNOTE-022, 2019 2.02 [0.07; 61.28]
MDX010 Ipi plus gp100 vs gp100, 2010 1.36 [0.28; 6.47]
1.74 [0.87 ; 3.49 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019, MDX010 Ipi plus gp100 vs gp100, 2010 17 0% 8,853 low low TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [2.72; 5.85]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.85 [3.25; 7.24]
CheckMate 069 (all population), 2015 4.18 [1.76; 9.91]
CheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19]
CheckMate 238, 2017 0.12 [0.08; 0.17]
EORTC 18071, 2015 21.35 [13.41; 33.97]
IMMUNED (N vs P ; all population), 2020 7.29 [0.86; 61.51]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.33 [4.34; 29.62]
IMMUNED (NI vs P ; all population), 2020 80.95 [10.39; 630.65]
KEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87]
KEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
KEYNOTE-022, 2019 2.67 [1.18; 6.03]
2.63 [1.23 ; 5.60 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF wild type), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, KEYNOTE-022, 2019 16 96% 6,907 low low TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs I ; all population), 2015 2.72 [1.82; 4.06]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.10 [3.17; 8.19]
CheckMate 069 (all population), 2015 4.14 [1.59; 10.74]
CheckMate 238, 2017 0.09 [0.05; 0.15]
IMMUNED (N vs P ; all population), 2020 9.90 [0.53; 186.01]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.38 [3.94; 32.84]
IMMUNED (NI vs P ; all population), 2020 112.65 [6.61; 1919.31]
KEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76]
KEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
2.30 [0.95 ; 5.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 13 94% 5,735 low low Abdominal pain TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 069 (all population), 2015 0.24 [0.01; 7.31]
CheckMate 238, 2017 0.50 [0.02; 14.96]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.64 [0.23 ; 1.82 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 11 0% 4,721 low low Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.59 [0.20 ; 12.46 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 069 (all population), 2015 0.24 [0.02; 2.68]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.58 [0.79 ; 3.16 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 14 0% 6,910 low low Alopecia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.24 ; 3.81 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 2,501 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
KEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88]
KEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81]
KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.45 [0.15 ; 1.30 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 4% 2,501 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.01 [0.18; 22.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.25 [0.01; 5.62]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 1.44 [0.48; 4.34]
KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.32 [0.68 ; 2.56 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 15 0% 6,942 low low Asthenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.50 [0.02; 14.88]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.25 [0.03; 2.24]
IMspire-150 (BRAF mutant), 2020 2.47 [0.45; 13.60]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.69 [0.32 ; 1.49 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 11 0% 5,607 low low Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
2.58 [0.36 ; 18.33 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.78 [0.09 ; 6.72 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020 3 0% 724 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.84 [0.17 ; 4.19 ] CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 1,531 low not evaluable Chorioretinopathy TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.61 [0.02 ; 18.27 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
CA184-024, 2011 10.35 [0.56; 190.49]
CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs I ; all population), 2015 1.08 [0.61; 1.93]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 9.36 [2.80; 31.26]
CheckMate 069 (all population), 2015 2.94 [0.81; 10.66]
EORTC 18071, 2015 39.14 [5.34; 286.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.40 [0.31; 130.93]
IMMUNED (NI vs P ; all population), 2020 5.83 [0.28; 119.27]
KEYNOTE 054 (all population), 2018 10.04 [1.28; 78.73]
KEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13]
KEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
MDX010 Ipi plus gp100 vs gp100, 2010 8.58 [0.50; 146.20]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.58 [0.22; 1.50]
MDX010 Ipi vs gp100, 2010 14.85 [0.83; 264.38]
1.90 [0.91 ; 3.97 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 18 78% 8,570 low low Constipation TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.96 [0.20 ; 4.56 ] CheckMate 066, 2015, CheckMate 069 (all population), 2015, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 2,317 moderate not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.25 [0.01; 5.54]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.97 [0.28 ; 3.31 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 0% 3,676 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 4.01 [0.45; 36.11]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 8.09 [0.43; 153.69]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 0.30 [0.01; 6.77]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.28 [0.49 ; 3.33 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 13 0% 5,026 low critical Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 9.95 [0.54; 182.62]
KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
2.03 [0.51 ; 8.05 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-006 (3 week), 2015 6 0% 2,773 low serious Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
CA184-024, 2011 21.14 [1.23; 363.94]
CheckMate 066, 2015 2.00 [0.18; 22.23]
CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs I ; all population), 2015 1.66 [0.90; 3.06]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.45 [1.60; 7.41]
CheckMate 069 (all population), 2015 0.98 [0.31; 3.04]
CheckMate 238, 2017 0.15 [0.07; 0.34]
EORTC 18071, 2015 25.54 [6.16; 105.87]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.06; 16.70]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
IMspire-150 (BRAF mutant), 2020 0.53 [0.16; 1.76]
KEYNOTE 054 (all population), 2018 1.32 [0.29; 5.92]
KEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81]
KEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17]
KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
MDX010 Ipi plus gp100 vs gp100, 2010 5.01 [0.65; 38.48]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.30; 2.12]
MDX010 Ipi vs gp100, 2010 6.29 [0.75; 52.98]
1.31 [0.77 ; 2.23 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 21 73% 10,397 low low Dizziness TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.95 [0.10 ; 9.23 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.37 [0.62; 3.04]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.32 [0.68 ; 2.53 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 0% 4,886 low low Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.95 [0.10 ; 9.23 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.95 [0.10 ; 9.23 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.76 [0.65 ; 4.80 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 0% 4,416 low low Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.97 [0.06 ; 15.73 ] IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 217 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
CheckMate 069 (all population), 2015 1.24 [0.23; 6.63]
EORTC 18071, 2015 42.70 [5.84; 312.15]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.50 [0.62; 48.70]
IMMUNED (NI vs P ; all population), 2020 10.10 [0.54; 189.78]
KEYNOTE 054 (all population), 2018 18.05 [1.04; 312.27]
MDX010 Ipi plus gp100 vs gp100, 2010 2.80 [0.15; 53.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.27 [0.07; 1.01]
MDX010 Ipi vs gp100, 2010 10.44 [0.56; 193.00]
3.45 [1.24 ; 9.62 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 10 62% 4,432 low low Erythema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 7.41 [0.37; 148.78]
7.41 [0.37 ; 148.78 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results A3671009, 2013 0.98 [0.02; 49.62]
Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.13 [0.23 ; 5.64 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 5 0% 1,694 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.25 [0.01; 5.51]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs I ; all population), 2015 4.45 [1.26; 15.77]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.48 [1.26; 15.87]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 3.70 [0.38; 35.82]
KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10]
KEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11]
KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
1.01 [0.50 ; 2.04 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 14 42% 5,931 low low Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
IMMUNED (NI vs P ; all population), 2020 3.81 [0.17; 86.56]
2.81 [0.41 ; 19.25 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
CheckMate 069 (all population), 2015 2.22 [0.77; 6.34]
CheckMate 238, 2017 0.10 [0.05; 0.20]
EORTC 18071, 2015 22.61 [8.20; 62.34]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 9.36 [1.13; 77.61]
IMMUNED (NI vs P ; all population), 2020 17.19 [0.96; 307.68]
KEYNOTE 054 (all population), 2018 5.01 [1.09; 22.98]
MDX010 Ipi plus gp100 vs gp100, 2010 8.05 [1.07; 60.32]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.74 [0.34; 1.61]
MDX010 Ipi vs gp100, 2010 10.83 [1.37; 85.84]
3.03 [1.01 ; 9.08 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 90% 5,337 low low General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
IMMUNED (NI vs P ; all population), 2020 3.81 [0.17; 86.56]
2.81 [0.41 ; 19.25 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 069 (all population), 2015 1.98 [0.09; 44.77]
CheckMate 238, 2017 0.14 [0.02; 1.15]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.84 [0.32 ; 2.19 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 11 0% 4,721 low low Hepatitis TRAE (grade 3-4)detailed results A3671009, 2013 3.94 [0.18; 87.81]
Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CA184-024, 2011 6.16 [0.31; 123.62]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 10.08 [0.55; 185.32]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.15 [0.55; 186.51]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.31 [0.64; 17.15]
IMMUNED (NI vs P ; all population), 2020 12.37 [0.67; 227.41]
KEYNOTE 054 (all population), 2018 6.99 [0.86; 56.99]
KEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
3.47 [1.87 ; 6.43 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 18 0% 8,269 low low Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 15.93 [0.93; 273.74]
CheckMate 238, 2017 0.15 [0.07; 0.32]
EORTC 18071, 2015 57.44 [7.90; 417.44]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 7.53 [1.60; 35.49]
IMMUNED (NI vs P ; all population), 2020 28.19 [1.62; 491.24]
MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2.78 [0.15; 52.88]
MDX010 Ipi vs gp100, 2010 0.16 [0.01; 3.32]
2.83 [0.51 ; 15.67 ] CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 9 86% 3,600 low serious Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 238, 2017 2.01 [0.07; 59.97]
2.68 [0.38 ; 18.88 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 066, 2015, CheckMate 238, 2017 3 0% 2,042 low not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.95 [0.10 ; 9.23 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.05 [0.30; 121.25]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 1.00 [0.06; 16.07]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.40 [0.31; 130.93]
IMMUNED (NI vs P ; all population), 2020 5.83 [0.28; 119.27]
IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.88 [0.81 ; 4.36 ] CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 16 0% 7,440 low critical Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.28; 3.47]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.06 [0.59; 43.61]
CheckMate 069 (all population), 2015 0.48 [0.07; 3.51]
CheckMate 238, 2017 0.18 [0.04; 0.81]
EORTC 18071, 2015 44.19 [2.67; 732.31]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.05; 2.45]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
0.96 [0.52 ; 1.76 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 18 24% 8,977 low low Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CA184-024, 2011 1.02 [0.02; 51.42]
CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.99 [0.43 ; 2.25 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 19 0% 8,941 low low Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
CA184-024, 2011 52.70 [7.19; 385.99]
CheckMate 066, 2015 1.00 [0.06; 16.02]
CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs I ; all population), 2015 9.98 [2.31; 43.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.68 [1.96; 22.80]
CheckMate 069 (all population), 2015 7.32 [0.41; 131.94]
CheckMate 238, 2017 0.10 [0.02; 0.44]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.01 [0.75; 12.00]
IMMUNED (NI vs P ; all population), 2020 17.19 [0.96; 307.68]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 0.17 [0.02; 1.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
2.22 [0.86 ; 5.74 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 16 68% 7,231 low low Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
CA184-024, 2011 32.40 [7.79; 134.72]
CheckMate 066, 2015 2.00 [0.18; 22.23]
CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs I ; all population), 2015 5.78 [2.20; 15.21]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.29 [2.52; 21.10]
CheckMate 069 (all population), 2015 10.83 [0.62; 189.76]
CheckMate 238, 2017 0.18 [0.07; 0.48]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.47 [1.46; 20.45]
IMMUNED (NI vs P ; all population), 2020 31.26 [1.80; 542.70]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
2.78 [1.13 ; 6.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 16 76% 7,231 low low Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs I ; all population), 2015 3.04 [1.54; 5.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.60 [1.37; 4.95]
CheckMate 069 (all population), 2015 4.19 [0.51; 34.53]
IMMUNED (N vs P ; all population), 2020 0.91 [0.17; 4.70]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.01 [0.75; 12.00]
IMMUNED (NI vs P ; all population), 2020 2.72 [0.68; 10.90]
IMspire-150 (BRAF mutant), 2020 0.99 [0.64; 1.52]
1.82 [1.19 ; 2.78 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020 9 42% 3,575 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
1.45 [0.27 ; 7.62 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 5 0% 1,461 low serious Leucopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.12 [0.01; 2.33]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17]
KEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17]
0.19 [0.05 ; 0.74 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 6 0% 1,434 low serious Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
CheckMate 238, 2017 0.05 [0.00; 0.95]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
IMspire-150 (BRAF mutant), 2020 1.36 [0.78; 2.37]
KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.48 [0.95 ; 2.30 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 15 0% 6,657 low low Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.06; 16.70]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.44 [0.23 ; 8.93 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.16 [0.01; 3.31]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.95 [0.11 ; 8.51 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 25% 324 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
KEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50]
KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.15 [0.48 ; 2.76 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 13 0% 5,026 low critical Myocarditis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.19 ; 4.71 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 2,402 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 3.53 [0.73; 17.15]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 14.30 [0.81; 253.04]
CheckMate 069 (all population), 2015 0.48 [0.03; 7.91]
CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 0.17 [0.02; 1.40]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.84 [0.40 ; 1.76 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 15 0% 6,942 low low Nephritis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 3.96 [0.18; 87.96]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.03 [0.15 ; 6.90 ] KEYNOTE 054 (all population), 2018, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 2,078 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
EORTC 18071, 2015 18.45 [1.07; 319.15]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.04; 5.68]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
3.11 [0.83 ; 11.67 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 5 4% 1,995 low not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.05 [0.00; 0.92]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39]
KEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.23 [0.07 ; 0.79 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 2,501 moderate serious Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.95 [0.10 ; 9.23 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 324 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.06; 15.81]
KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
1.56 [0.46 ; 5.29 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 8 0% 3,404 low not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 066, 2015 0.16 [0.01; 3.29]
0.50 [0.04 ; 5.71 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 066, 2015 2 14% 1,137 low not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.77 [0.20 ; 2.91 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 2,501 moderate serious Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
KEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29]
KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32]
0.92 [0.24 ; 3.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 6 0% 1,749 low not evaluable Peripheral oedema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84]
1.22 [0.02 ; 61.84 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 3.00 [0.31; 29.00]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
CheckMate 069 (all population), 2015 0.98 [0.09; 11.08]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
KEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
2.13 [0.97 ; 4.66 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 14 0% 6,352 low low Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.78 [0.18 ; 3.32 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,807 low not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
CA184-024, 2011 10.35 [0.56; 190.49]
CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.10 [0.73; 50.95]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
CheckMate 238, 2017 0.10 [0.01; 1.82]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.53 [0.78 ; 3.02 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 20 0% 9,452 low critical Pyrexia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.50 [0.02; 14.88]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
IMMUNED (NI vs P ; all population), 2020 3.81 [0.17; 86.56]
IMspire-150 (BRAF mutant), 2020 1.22 [0.24; 6.13]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.38 [0.60 ; 3.16 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020, IMMUNED (NI vs P ; all population), 2020, IMspire-150 (BRAF mutant), 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 12 0% 5,232 low low Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CA184-024, 2011 6.16 [0.31; 123.62]
CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 2.02 [0.68; 5.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.30 [1.31; 80.93]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
CheckMate 238, 2017 0.35 [0.13; 0.98]
EORTC 18071, 2015 10.16 [0.55; 186.52]
IMspire-150 (BRAF mutant), 2020 0.98 [0.53; 1.81]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 3.51 [0.19; 64.62]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.73 [0.20; 14.97]
MDX010 Ipi vs gp100, 2010 2.02 [0.07; 60.83]
1.33 [0.82 ; 2.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, IMspire-150 (BRAF mutant), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 18 13% 10,073 low low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
CheckMate 238, 2017 1.00 [0.02; 50.62]
0.99 [0.08 ; 12.98 ] CheckMate 069 (all population), 2015, CheckMate 238, 2017 2 0% 1,045 low not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-14 15:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743